Benefit versus Risk in Statin Treatment
References (25)
- et al.
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA)a multicentre randomised controlled trial
Lancet
(2003) - et al.
Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS)multicentre randomised placebo-controlled trial
Lancet
(2004) The liver and lovastatin
Am J Cardiol
(2002)Statins, cardiovascular disease, and drug safety
Am J Cardiol
(2006)- et al.
Statin safetya systematic review
Am J Cardiol
(2006) - et al.
Effectiveness of statin therapy in adults with coronary heart disease
Arch Intern Med
(2004) MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individualsa randomised placebo-controlled trial
Lancet
(2002)Heart and Stroke Facts 2005 Statistical Update. [American Heart Association Web site.]
(2005)- et al.
Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and strokesystematic review and meta-analysis [review]
BMJ
(2003) Randomised trial of cholesterol lowering in 4444 patients with coronary heart diseasethe Scandinavian Simvastatin Survival Study (4S)
Lancet
(1994)
Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
N Engl J Med
Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
N Engl J Med
Cited by (58)
Effectiveness of local application of simvastatin for prevention of bisphosphonate-related osteonecrosis of the jaw: An animal study on rats
2022, Journal of Oral and Maxillofacial Surgery, Medicine, and PathologyCitation Excerpt :This study was the first to assess the efficacy of local single-dose application of simvastatin for the prevention of MRONJ. Local application of simvastatin has the advantages of prevention of its hepatic metabolism, enabling the delivery of adequate dosage of the medication to the desired site, and eliminating the need for high doses of simvastatin, which would have many side effects [26]. Also, the single-dose application of simvastatin does not require patient cooperation and eliminates the need for multiple visits.
Self-healing DNA-based injectable hydrogels with reversible covalent linkages for controlled drug delivery
2020, Acta BiomaterialiaCitation Excerpt :Precisely, simvastatin can promote osteogenic differentiation of stem cells by augmenting the expression levels of alkaline phosphatase and bone morphogenic proteins [12]. However, high dosages of simvastatin can induce adverse side effects in several organs such as liver and kidneys, whereas low doses are inadequate for complete bone healing [13,14]. Hence, to achieve the desired beneficial effects it is necessary to deliver simvastatin locally at a constant therapeutic concentration.
Formulation of transdermal nanoemulsion gel drug delivery system of lovastatin and its in vivo characterization in glucocorticoid induced osteoporosis rat model
2019, Journal of Drug Delivery Science and TechnologyCitation Excerpt :Due to extensive first pass metabolism, the amount of statins reaching the bone tissue after oral administration was considerably insignificant and thus could not stimulate bone formation processes. Moreover administering higher doses of statins orally had resulted in serious side effects such as risk of liver failure, kidney disease, rhabdomyolysis or inflammation [8,9]. For local delivery of statins, multiple injections near bone repair sites [10,11] or special drug delivery systems [12–14] were developed which were quite invasive techniques.
Impact of pharmacogenetics on statin-induced myopathy in South-Indian subjects
2018, Indian Heart JournalCitation Excerpt :3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors or statins are widely used drugs in the reduction of cardiovascular events in patients with dyslipidemia, one of the main risk factor for coronary artery disease.1 On the other hand, statin-related severe adverse events are reported in patients treated with statins due to oxidative stress, abnormal mitochondrial function, and imbalance of muscular calcium homeostasis leading to muscular side effects, a common cause of withdrawal and statin discontinuation.2–6 Statins are associated with adverse clinical effects such as myalgia, myositis, rhabdomyolysis, muscle weakness, muscle cramps, and creatine kinase (CK) elevations after statin withdrawal.4–6
An assessment by the statin intolerance panel: 2014 update
2014, Journal of Clinical Lipidology